Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson Sells 2,657 Shares of Stock

Boston Scientific Co. (NYSE:BSX) EVP John Bradley Sorenson sold 2,657 shares of Boston Scientific stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $104.41, for a total transaction of $277,417.37. Following the sale, the executive vice president now owns 24,294 shares in the company, valued at approximately $2,536,536.54. This represents a 9.86 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

John Bradley Sorenson also recently made the following trade(s):

• On Friday, February 14th, John Bradley Sorenson sold 1,201 shares of Boston Scientific stock. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31.
• On Wednesday, February 12th, John Bradley Sorenson sold 6,389 shares of Boston Scientific stock. The shares were sold at an average price of $105.06, for a total value of $671,228.34.
• On Friday, February 7th, John Bradley Sorenson sold 6,528 shares of Boston Scientific stock. The shares were sold at an average price of $104.97, for a total value of $685,244.16.
• On Thursday, January 2nd, John Bradley Sorenson sold 4,119 shares of Boston Scientific stock. The stock was sold at an average price of $90.02, for a total value of $370,792.38.

Boston Scientific Trading Up 0.3 %

Shares of BSX stock opened at $105.63 on Thursday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The company has a market capitalization of $155.68 billion, a price-to-earnings ratio of 84.50, a PEG ratio of 2.81 and a beta of 0.80. Boston Scientific Co. has a 52-week low of $65.33 and a 52-week high of $107.17. The company has a 50-day simple moving average of $97.39 and a two-hundred day simple moving average of $88.94.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. Research analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on BSX shares. Barclays increased their target price on shares of Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. StockNews.com raised shares of Boston Scientific from a “hold” rating to a “buy” rating in a research note on Wednesday, January 29th. Royal Bank of Canada upped their price target on shares of Boston Scientific from $105.00 to $116.00 and gave the company an “outperform” rating in a research report on Thursday, February 6th. Piper Sandler lifted their price objective on Boston Scientific from $95.00 to $115.00 and gave the stock an “overweight” rating in a research report on Monday, February 3rd. Finally, Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a research note on Thursday, February 6th. One investment analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Boston Scientific has a consensus rating of “Buy” and an average price target of $107.39.

Hedge Funds Weigh In On Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Warm Springs Advisors Inc. bought a new stake in Boston Scientific in the fourth quarter worth about $652,000. GF Fund Management CO. LTD. bought a new stake in shares of Boston Scientific in the 4th quarter worth approximately $2,791,000. Parr Mcknight Wealth Management Group LLC purchased a new position in Boston Scientific in the fourth quarter valued at approximately $2,139,000. Vega Investment Solutions bought a new position in Boston Scientific during the fourth quarter valued at $1,287,000. Finally, Investment Management Corp VA ADV purchased a new stake in Boston Scientific in the fourth quarter worth $25,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.